{"id":"lmw-heparin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Injection site hematoma"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LMW heparin is derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in shorter chain lengths. It preferentially inhibits Factor Xa over Factor IIa, providing a more predictable pharmacokinetic profile and improved bioavailability compared to unfractionated heparin. This selective anticoagulant activity makes it suitable for both therapeutic and prophylactic use in thrombotic conditions.","oneSentence":"Low-molecular-weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:13.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis"},{"name":"Treatment of deep vein thrombosis"},{"name":"Treatment of pulmonary embolism"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT05249790","phase":"PHASE3","title":"Anti-inflammatory Drug Algorithm for COVID-19 Home Treatment","status":"WITHDRAWN","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2022-02-24","conditions":"COVID-19","enrollment":""},{"nctId":"NCT06512233","phase":"NA","title":"Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival","status":"NOT_YET_RECRUITING","sponsor":"Aga Khan University","startDate":"2025-01","conditions":"Complication,Postoperative","enrollment":126},{"nctId":"NCT05413642","phase":"PHASE3","title":"COVID-19 Algorithm Treatment at Home","status":"WITHDRAWN","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2023-07-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04854824","phase":"","title":"A Simple Approach to Prevent Hospitalization for COVID-19 Patients","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-07-01","conditions":"Covid19","enrollment":216},{"nctId":"NCT04794998","phase":"","title":"A Simple Approach to Treat COVID-19 Patients at Home.","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-02-08","conditions":"COVID 19","enrollment":180},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT02073682","phase":"PHASE3","title":"Cancer Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-07-16","conditions":"Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":1046},{"nctId":"NCT00986154","phase":"PHASE3","title":"Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-10","conditions":"Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":8292},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT00238667","phase":"PHASE3","title":"To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2005-11","conditions":"Cervical Artery Dissection, Carotid Artery Dissection, Vertebral Artery Dissection","enrollment":250},{"nctId":"NCT02375646","phase":"NA","title":"Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2015-05","conditions":"Post Polypectomy Bleeding in Anticoagulated Patients, Gastrointestinal Hemorrhage","enrollment":286},{"nctId":"NCT00395772","phase":"PHASE2","title":"Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-12","conditions":"Venous Thromboembolism","enrollment":543},{"nctId":"NCT00790439","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07","conditions":"Diabetes Mellitus, Type I","enrollment":""},{"nctId":"NCT00067093","phase":"PHASE3","title":"Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-05","conditions":"Deep Vein Thrombosis","enrollment":1452},{"nctId":"NCT00004875","phase":"","title":"Heparin or Enoxaparin in Patients With Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"1996-07","conditions":"Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":6},{"nctId":"NCT01281800","phase":"PHASE2","title":"Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma","status":"UNKNOWN","sponsor":"Institute of Oncology Ljubljana","startDate":"2008-08","conditions":"Mesothelioma","enrollment":72},{"nctId":"NCT00062803","phase":"PHASE3","title":"SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT00370760","phase":"PHASE3","title":"Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2006-09","conditions":"Proliferative Vitreoretinopathy","enrollment":""},{"nctId":"NCT00371020","phase":"PHASE3","title":"The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2005-02","conditions":"Proliferative Vitreoretinopathy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"CAESAREAN SECTION"},{"count":3,"reaction":"DRUG EXPOSURE DURING PREGNANCY"},{"count":2,"reaction":"FOETAL DISORDER"},{"count":2,"reaction":"INTRA-UTERINE DEATH"},{"count":2,"reaction":"THROMBOSIS"},{"count":1,"reaction":"ABORTION INDUCED"},{"count":1,"reaction":"ACUTE PULMONARY OEDEMA"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ANAEMIA HAEMOLYTIC AUTOIMMUNE"},{"count":1,"reaction":"ANTEPARTUM HAEMORRHAGE"}],"_approvalHistory":[],"publicationCount":309,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"(LMW)heparin","genericName":"(LMW)heparin","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-molecular-weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa. Used for Venous thromboembolism prophylaxis, Treatment of deep vein thrombosis, Treatment of pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}